Cargando…
Resistant to amyloid-β or just waiting for disease to happen?
The post-mortem finding of abundant intracerebral accumulation of amyloid-β (Aβ) in the cerebral cortex of some people who develop minimal neurofibrillary pathology and remain cognitively intact until death (so-called pathological aging, or PA) challenges the orthodox view of the pathogenesis of Alz...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506933/ https://www.ncbi.nlm.nih.gov/pubmed/22643124 http://dx.doi.org/10.1186/alzrt122 |
_version_ | 1782250983009550336 |
---|---|
author | Love, Seth |
author_facet | Love, Seth |
author_sort | Love, Seth |
collection | PubMed |
description | The post-mortem finding of abundant intracerebral accumulation of amyloid-β (Aβ) in the cerebral cortex of some people who develop minimal neurofibrillary pathology and remain cognitively intact until death (so-called pathological aging, or PA) challenges the orthodox view of the pathogenesis of Alzheimer's disease (AD). This issue of Alzheimer's Research & Therapy reports a study by Moore and colleagues, of the McKnight Brain Institute (Gainesville, FL, USA) and the Mayo Clinic College of Medicine (Jacksonville, FL, USA), who have performed the most detailed analysis to date of the levels and types of Aβ that accumulate in such cases. Although the levels of the different forms of Aβ in prefrontal cortex from patients with AD tended to be higher than those from patients with PA, the authors found extensive overlap between the two groups and suggest that PA is likely to represent a prodromal stage of AD. It is also possible that the quantity of Aβ is less important than the extent to which it accumulates intraneuronally or that some people are resistant to its effects - perhaps because of genetically determined differences in the inflammatory and astrocytic reactions to Aβ. The study emphasizes the continuing importance of careful human clinical and post-mortem studies in elucidating the pathogenesis of this disease. |
format | Online Article Text |
id | pubmed-3506933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35069332012-11-30 Resistant to amyloid-β or just waiting for disease to happen? Love, Seth Alzheimers Res Ther Commentary The post-mortem finding of abundant intracerebral accumulation of amyloid-β (Aβ) in the cerebral cortex of some people who develop minimal neurofibrillary pathology and remain cognitively intact until death (so-called pathological aging, or PA) challenges the orthodox view of the pathogenesis of Alzheimer's disease (AD). This issue of Alzheimer's Research & Therapy reports a study by Moore and colleagues, of the McKnight Brain Institute (Gainesville, FL, USA) and the Mayo Clinic College of Medicine (Jacksonville, FL, USA), who have performed the most detailed analysis to date of the levels and types of Aβ that accumulate in such cases. Although the levels of the different forms of Aβ in prefrontal cortex from patients with AD tended to be higher than those from patients with PA, the authors found extensive overlap between the two groups and suggest that PA is likely to represent a prodromal stage of AD. It is also possible that the quantity of Aβ is less important than the extent to which it accumulates intraneuronally or that some people are resistant to its effects - perhaps because of genetically determined differences in the inflammatory and astrocytic reactions to Aβ. The study emphasizes the continuing importance of careful human clinical and post-mortem studies in elucidating the pathogenesis of this disease. BioMed Central 2012-05-30 /pmc/articles/PMC3506933/ /pubmed/22643124 http://dx.doi.org/10.1186/alzrt122 Text en Copyright ©2012 BioMed Central Ltd |
spellingShingle | Commentary Love, Seth Resistant to amyloid-β or just waiting for disease to happen? |
title | Resistant to amyloid-β or just waiting for disease to happen? |
title_full | Resistant to amyloid-β or just waiting for disease to happen? |
title_fullStr | Resistant to amyloid-β or just waiting for disease to happen? |
title_full_unstemmed | Resistant to amyloid-β or just waiting for disease to happen? |
title_short | Resistant to amyloid-β or just waiting for disease to happen? |
title_sort | resistant to amyloid-β or just waiting for disease to happen? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506933/ https://www.ncbi.nlm.nih.gov/pubmed/22643124 http://dx.doi.org/10.1186/alzrt122 |
work_keys_str_mv | AT loveseth resistanttoamyloidborjustwaitingfordiseasetohappen |